Back to Journals » OncoTargets and Therapy » Volume 9
Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: comments on a meta-analysis by Liang et al
Authors Tu C, He J, Li Z
Received 11 January 2016
Accepted for publication 11 January 2016
Published 5 April 2016 Volume 2016:9 Pages 2017—2018
DOI https://doi.org/10.2147/OTT.S104004
Checked for plagiarism Yes
Editor who approved publication: Professor Daniele Santini
Chao Tu,1 Jieyu He,2 Zhihong Li3
1Department of Geriatric Surgery, 2Department of Geriatrics, 3Department of Orthopedics and Institute of Senile and Aging Diseases, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China
Recently, we read with deep interest a meta-analysis by Liang et al entitled “Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis” published in OncoTargets and Therapy. In this article, the investigators systematically reviewed the trials on the effects of IGF-1R expression in various bone and soft tissue sarcomas (BSTSs) and performed a meta-analysis. They reached an important conclusion that elevated IGF-1R expression was associated with poor overall survival in BSTS patients. Furthermore, subgroup analysis revealed that IGF-1R level was negatively correlated with prognosis in osteosarcoma but not significantly associated with Ewing’s sarcoma. We sincerely appreciate the tremendous effort made by the investigators. Nevertheless, before their results can be accepted, some worthwhile issues need to be addressed first.
View original article by Liang et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.